Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/E ratio high or low?
The P/E ratio of 2.19 is in line with its 1-year average of 2.16, near the high end of its 1-year range (2.07–2.21).
As of 2026-10-06T18:05:13.517Z.
Calculation as of: 2026-10-06T18:05:13.517Z.
Quote observation: 2026-10-06T17:59:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 196692da0c380a40ac90dfab7941532e3601431322d0ea6e9ae3bdc8429e964f
PE Ratio (2.19) = Close Price ($17.12) / Diluted TTM EPS ($7.82)
PE RATIO
2.19
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
25.63
median of 186 covered companies
CURRENT VS SECTOR MEDIAN
-91.46%
vs the sector median at left
Market Cap
$88.62M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$92.33M
PE Ratio
N/A
TTM Avg
13.33
3Y Avg
13.33
5Y Avg
13.33
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rallybio Corporation (RLYB) | $90.85M | 2.19 | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $90.41M | N/A | N/A | N/A | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $91.46M | N/A | N/A | N/A | N/A |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.33M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $89.53M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $89.45M | 30.16 | 45.53 | 45.53 | 24.63 |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $88.62M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $92.33M | N/A | 13.33 | 13.33 | 13.33 |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 115.25 | 46.83 | 44.28 | 282.12 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.91M | N/A | 3.67 | 3.67 | 3.67 |
At 2.2, P/E is above its 1-year median — higher than 88% of readings in its 1-year history.
1-year low
2.1
median
2.2
1-year high
2.2
Trailing P/E
2.2
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$17.12
Forward EPS (Est.)
$-5.52
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2026-10-05 | 2.17 |
| 2026-10-02 | 2.19 |
| 2026-10-01 | 2.15 |
| 2026-09-30 | 2.21 |
| 2026-09-29 | 2.21 |
| 2026-09-28 | 2.19 |
| 2026-09-25 | 2.13 |
| 2026-09-24 | 2.13 |
| 2026-09-23 | 2.16 |
| 2026-09-22 | 2.17 |
| 2026-09-21 | 2.17 |
| 2026-09-18 | 2.20 |
| 2026-09-17 | 2.20 |
| 2026-09-16 | 2.19 |
| 2026-09-15 | 2.21 |
| 2026-09-14 | 2.12 |
| 2026-09-11 | 2.16 |
| 2026-09-10 | 2.15 |
| 2026-09-09 | 2.18 |
| 2026-09-08 | 2.13 |
| 2026-09-04 | 2.17 |
| 2026-09-03 | 2.16 |
| 2026-09-02 | 2.17 |
| 2026-09-01 | 2.14 |
| 2026-08-31 | 2.15 |
| 2026-08-28 | 2.16 |
| 2026-08-27 | 2.15 |
| 2026-08-26 | 2.16 |
| 2026-08-25 | 2.17 |
| 2026-08-24 | 2.15 |
| 2026-08-21 | 2.16 |
| 2026-08-20 | 2.13 |
| 2026-08-19 | 2.18 |
| 2026-08-18 | 2.15 |
| 2026-08-17 | 2.18 |
| 2026-08-14 | 2.18 |
| 2026-08-13 | 2.17 |
| 2026-08-12 | 2.13 |
| 2026-08-11 | 2.10 |
| 2026-08-10 | 2.13 |
| 2026-08-07 | 2.07 |